DETAILED ACTION
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
The response filed September 1, 2026, has been received and entered.
Election/Restrictions
Applicant’s election without traverse of Group I, claims 1-10, in the reply filed on September 1, 2026, is acknowledged.
Claim 11 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Claims 1-10 are examined on the merits.
Claim Objections
Claims 1-10 are objected to because of the following informalities:
Claim 1 is objected to because of the recitation “670nm” in lines 9 and 10. The recitation should be substituted with “670 nm”. Since claim 1 is objected to, then its dependent claims, claims 2-10, are objected to.
Claim 2 is objected to because of the recitation “670nm” in line 4. The recitation should be substituted with “670 nm”. Also, claim 2 is objected to because the following recitation in lines 5-9: “wherein the points of the first cloud correspond to the Brettanomyces spp cells and that the points of the second cloud correspond to the Saccharomyces spp cells and the number of Brettanomyces spp and/or Saccharomyces spp cells is optionally enumerated by counting the points of each of the clouds.” The grammar of the recitation should be corrected. It is suggested that it be amended to the following:
wherein the points of the first cloud correspond to the Brettanomyces spp cells, the points of the second cloud correspond to the Saccharomyces spp cells, and the number of Brettanomyces spp and/or Saccharomyces spp cells is optionally enumerated by counting the points of each of the clouds.
Since claim 2 is objected to, then its dependent claims, claims 5 and 6, are objected to.
Claim 3 is objected to because of the recitation “670nm” in the last line. The recitation should be substituted with “670 nm”.
Claim 4 is objected to because of its grammar. First, the recitation “being” in line 2 should be substituted with “is.” The recitation “in that” in lines 3, 5, and 6 should be deleted. The recitation “fluorochrome” in line 7 should be substituted with “fluorochromes” (i.e., line 7 should recite “the first and second fluorochromes”). The recitation “that of the” in line 9 should be deleted. The recitation “fluorochrome” in line 10 should be substituted with “fluorochromes” (i.e., lines 9-10 should recite “the first and second fluorochromes”). Also, it is noted that the strike-through line through the claim number should be removed.
Claim 5 is objected to because of its grammar. First, the recitation “in that” in line 2 should be deleted. The recitation “fluorochrome” in line 3 should be substituted with “fluorochromes” (i.e., line 3 should recite “the first and second fluorochromes”). The recitation “that of the” in line 5 should be deleted. The recitation “fluorochrome” in line 5 should be substituted with “fluorochromes” (i.e., line 5 should recite “the first and second fluorochromes”). Also, it is noted that the strike-through line through the claim number should be removed. Since claim 5 is objected to, then its dependent claim, claim 6, is objected to.
Claim 7 is objected to because a space is missing between the number and the units for wavelengths. In particular, claim 7 is objected to because of the recitations “599nm” and “657nm” in line 4, “619nm” in line 5, “678nm” in line 6, “657nm” and “673nm” in line 11, “547nm” and “570nm” in line 14, “657nm” in line 17, “673nm” in line 18, “547nm” in line 23, and “570nm” in line 24. For instance, the recitation “599nm” should be substituted with “599 nm”.
Also, claim 7 is objected to because the recitation “and” should be deleted after the recitation “0.27” in line 10, and a comma should be inserted in its place. The recitation “in that” in line 25 should be deleted. Claim 7 is also objected to because it does not end with a period.
Also, claim 7 is objected to because the word “the” should be inserted before the recitation “wall” in line 22.
Claim 9 is objected to because a colon should be inserted after the recitation “the following species” in line 3. Also, the recitation “and” in line 4 of claim 9 should not be italicized.
Claim 10 is objected to because the recitation “637nm” should be substituted with “637 nm”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 recites the limitation "the first cloud" in lines 11-12. There is insufficient antecedent basis for this limitation in the claim. It is unclear whether it is referring to the “first point cloud” as recited in line 9. Since claim 1 is indefinite, then its dependent claims, claims 2-10, are rendered indefinite. Therefore, claims 1-10 are rejected under 35 U.S.C. 112(b). For the purpose of applying prior art, “the first cloud” recited in lines 11-13 is being interpreted as the “first point cloud.”
Claim 2 is indefinite because it is unclear whether “a first cloud” in line 3 is referring to one of the two point clouds (i.e., a first point cloud). Also, there is insufficient antecedent basis for the limitation “the second cloud” in lines 6-7. It is unclear whether it is referring to the “second point cloud.” Since claim 2 is indefinite, then its dependent claims, claims 5 and 6, are rendered indefinite. Thus, claims 2, 5, and 6 are rejected under 35 U.S.C. 112(b). For the purpose of applying prior art, any recitation of a “cloud” is being interpreted as a “point cloud.”
Claim 3 is rendered indefinite by the recitation “before measuring the fluorescence.” This recitation lacks antecedent basis because parent claim 1 does not recite measuring the fluorescence.
Also, claim 3 is indefinite because the recitation of a “second window which corresponds to points attributable to bacterial cells” is confusing. That recitation is confusing because it is unclear that the organic liquid substrate, or the sample of the substrate, comprises bacterial cells.
Further regarding claim 3, the recitation “the biparametric histogram is plotted giving the fluorescence intensity…” in the last three lines is confusing because there is a prior recitation in line 4 that the biparametric histogram is plotted. It is unclear whether claim 3 requires that the biparametric histogram is plotted twice.
Claim 4 is rendered indefinite by the recitation “a third window that surrounds the points of the first cloud.” The recitation implies a first window and a second window, but there is recitation of those windows in parent claim 1. Because of the lack of recitation of first and second windows, then the recitation of a third window is confusing.
Also, claim 4 is confusing because of the grammar. In particular, claim 4 recites “a biparametric histogram is also plotted giving for each point the fluorescence intensity of the first and that of the second fluorochrome or the fluorescence intensity per unit of surface area of one of the two fluorochromes and that due to the other fluorochrome and in that, furthermore, two groups of points are determined” in lines 8-12. It appears that it requires that each point gives the fluorescence intensity of the first and second fluorochromes, or each point gives the fluorescence intensity per unit of surface area of one of the two fluorochromes. But it is unclear what is meant by “and that due to other fluorochrome and in that.”
Additionally, claim 4 is rendered indefinite by the recitation “which corresponds to the number of live Brettanomyces spp cells for the second group and the number of dead Brettanomyces spp cells for the first group” in the last three lines. It is unclear what is corresponding to the two recited numbers. It is unclear whether it is reciting that the second group of points corresponds to the number of live Brettanomyces spp cells, and the first group of points corresponds to the number of dead Brettanomyces spp cells.
Claim 5 recites the limitation "the second window" and the limitation “the…second fluorochrome” in lines 2 and 3, respectively. There is insufficient antecedent basis for these limitations in the claim. Parent claims 1 and 2 do not recite a second window, or even a first window, nor do they recite a second fluorochrome.
Also, claim 5 is rendered indefinite by the recitation “and that due to the other fluorochrome” in lines 6-7. It is unclear what is meant by “and that due to the other fluorochrome.”
Additionally, claim 5 is rendered indefinite by the recitation “which corresponds to the number of live bacterial cells for the second group and the number of dead bacterial cells for the first group.” First, the recitation of “live bacterial cells” and “dead bacterial cells” is confusing because there is no prior recitation that the organic liquid substrate or the sample of the substrate comprises bacterial cells. Also, it is unclear what corresponding to the two numbers. It is unclear whether it is recited that the second group corresponds to the number of live bacterial cells, and the first group corresponds to the number of dead bacterial cells.
Since claim 5 is indefinite, then its dependent claim, claim 6 is rendered indefinite. Therefore, claims 5 and 6 are rejected under 35 U.S.C. 112(b).
Claim 6 is rendered indefinite by the recitation “for the points of the second and/or third window” in line 5. It is unclear what is “for the points.” Also, there is insufficient antecedent basis for the limitation “third window” in the claim.
Additionally, claim 6 is rendered indefinite by the recitation “Brettanomyces spp/bacterial cells” in lines 11, 14-15, and 17. First, it is unclear how the forward slash modifies the terms. It is unclear whether it is used in place of “and,” “or,” or “and/or.” Second, the recitation of bacterial cells is confusing because there is no prior recitation that the organic liquid substrate or the sample of the substrate comprises bacterial cells.
Claim 6 is also rendered indefinite by the recitation “first/second fluorochrome” in lines 13 and 16. It is unclear how the forward slash modifies the terms. It is unclear whether it is used in place of “and,” “or,” or “and/or.”
Furthermore, claim 6 is rendered indefinite by the recitation “these points correspond to dead Brettanomyces spp/bacterial cells” in the last line. Because of the grammar used in the claim, it is unclear whether “these points” are referring to the points of all three subgroups, or points of the third subgroup.
Claim 7 recites the limitation "the…second fluorochromes" in line 2. There is insufficient antecedent basis for this limitation in the claim. There is no prior recitation in claim 1 of a second fluorochrome.
Also, claim 7 is rendered indefinite by the recitation “the first and second fluorochromes are different and selected from fluorochromes capable of binding to the DNA of cells and having a maximum fluorescence absorption wavelength equal to or greater than 599nm and equal to or less than 657nm, a maximum fluorescence emission wavelength equal to or greater than 619nm and equal to or less than 678nm and a quantum yield equal to or greater than 0.16 and equal to or less than 0.39 and mixtures thereof.” Because of the grammar, the fluorochromes of the group for selection are unclear, since it appears to list only one type of fluorochromes possessing all the properties listed. It is also unclear how a single fluorochrome can be a mixture of the recite fluorochromes. For the purpose of applying prior art, the recitation is interpreted as:
wherein the first and second fluorochromes are different and are fluorochromes capable of binding to the DNA of cells; have a maximum fluorescence absorption wavelength equal to or greater than 599 nm, and equal to or less than 657 nm; have a maximum fluorescence emission wavelength equal to or greater than 619nm, and equal to or less than 678 nm; and have a quantum yield equal to or greater than 0.16, and equal to or less than 0.39.
Regarding claim 7, the phrase "in particular" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). The term is recited in line 7, so it is unclear whether the limitations after “in particular,” spanning from line 7 to the last line, are part of the claimed invention.
Claim 7 recites the limitation "the third fluorochrome" in line 25. There is insufficient antecedent basis for this limitation in the claim. There is no prior recitation in claim 7 or parent claim 1 of a third fluorochrome.
Also, claim 7 is rendered indefinite by the recitation “mixtures of 5-carboxyfluorescein diacetate and 6-carboxyfluorescein diacetate and 5,6 carboxylate fluorescein diacetate succinimidyl ester of the following general formula (1)…” Because of the use of “and” and the lack of punctuation, the mixtures are unclear. It is unclear whether it recites mixtures comprising all three fluorochromes, or mixtures of 5-carboxyfluorescein diacetate and 6-carboxyfluorescein diacetate.
Claim 8 is rendered indefinite by the recitation “the substrate is selected from optionally…” The use of the term “optionally” makes it unclear what substrates can be selected. For the selection of a substrate, there must be at least some substrates for which the selection is not optional.
Regarding claim 8, the phrase "in particular" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).
Also, claim 8 is rendered indefinite by the recitation “in particular grape or apple” in line 3 because it is unclear whether it is referring to “grape or apple juices.”
Claim 8 is rendered indefinite by the recitation “in particular grape” in line 4 because it is unclear whether it is referring to “grape must.”
Claim 8 is rendered indefinite by the recitation “optionally sparkling” in the last line because it is unclear whether it is referring to sparkling finished wines.
Claim 9 is rendered indefinite by the recitation “from at least one other yeast species” in lines 4-5. It is unclear what is meant by the recitation. Because of the grammar (including lack of punctuation between the recitation and “B. naardenensis”), it is unclear how it relates to detecting, quantifying, and differentiating at least one Brettanomyces spp yeast species. The recitation of other yeast species is confusing because parent claim 1 does not recite that the organic liquid substrate or the sample of the substrate comprises other yeast.
Regarding claim 9, the phrase "in particular" in lines 5 and 11 renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Also, it is unclear how the recitation of “in particular from at least one Saccharomyces spp species” relates to any other limitation of the claim. It is unclear whether it is referring to the “at least one other yeast species.”
Regarding claim 10, the phrase "in particular" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).
Notice Re: Prior Art Available Under Both Pre-AIA and AIA
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-4, 8, and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Branco (International Journal of Food Microbiology. 2020. 314: 108415. 10 pages. Available online October 30, 2019. Listed on IDS filed 5/16/24), as evidenced by Van Dorpe (US 2015/0168392).
Branco discloses using flow cytometry for detecting Dekkera bruxellensis (i.e., Brettanomyces bruxellensis, as well known in the art; see page 1, lines 19-20 of the instant specification) in a wine environment (abstract). In particular, commercial white and red wine were artificially contaminated with D. bruxellensis cells, and then subjected to the RNA-FISH procedure described in Section 2.2.3 and analyzed by flow cytometry (FC) and epifluorescence microscopy (EM) (page 4, left column, third paragraph). White and red wine are directed to an ‘organic liquid substrate which contains fermentable sugars’ of instant claim 1, and meet embodiments of the substrate of instant claim 8. According to Section 2.2.3, a DNA-FISH probe stock solution is added to each FISH assay (page 3, left column, last paragraph). The species-specific probe for D. bruxellensis is the Dkb271-ATTO 647N probe, which is Dkb271 labeled with ATTO 647N in the 5’-end (page 3, left column, third paragraph through right column, first paragraph). As evidenced by Van Dorpe, the emission peak of the fluorescent label ATTO 647N is 670 nm (paragraph [0096]). The addition of the Dkb271-ATTO 647N probe to the wine contaminated with D. bruxellensis cells is directed to adding at least a first fluorochrome capable of binding to the DNA of dead and/or live cells to a sample of an organic liquid substrate (the wine) containing Brettanomyces spp yeast cells, meeting limitations of instant claim 1.
For the flow cytometry analysis of Branco, the percentage of cells that become fluorescent after Fluorescence In Situ Hybridization (FISH) treatment and their Fluorescence Intensities (FI), using the red (680/30) photodiode detector, were analyzed (page 3, right column, fourth paragraph). Therefore, the sample is irradiated so as to obtain the fluorescent emission of the first fluorochrome, meeting a limitation of instant claim 1. Moreover, the irradiation of the sample obtains a fluorescence emission at 670 nm because of the emission peak of 670 nm of ATTO 647N (as evidenced by Van Dorpe), further meeting another limitation of instant claim 1.
Branco differs from the claimed invention in that Branco does not show, from the sample of wine comprising Brettanomyces spp yeast cells, a biparametric histogram that is plotted to give for each point the fluorescence intensity due to the first fluorochrome and the fluorescence intensity emitted at 670 nm, wherein at least a first point cloud is obtained corresponding to a greater fluorescence intensity emitted and detected at 670 nm than that detected for the other points, wherein the points of the first point cloud correspond to the Brettanomyces spp cells.
However, for another experiment in Branco, the EU338-ATTO 647N probe was further included as a positive control for bacteria and a negative control for yeasts (page 3, paragraph bridging left and right columns). Figure 3C-H on page 7 show the dot-plots from the flow cytometry program, showing biparametric histograms which meet the claimed limitations.
Before the effective filing date, for situations when the wine sample comprises the Brettanomyces bruxellensis cells with other microorganisms, e.g. bacteria, as would have been expected when there is contamination in wine production (for instance, see the abstract), it would have been obvious to further include the other probes disclosed in Section 2.2.3, including the EU338-ATTO 647N probe, for performing the method of Branco involving a sample of wine comprising B. bruxellensis cells, in order to facilitate detection of microorganisms present in the wine. In doing so, then biparametric histograms would have been expected based in Figure 3C-H of Branco. Therefore, Branco renders obvious instant claims 1, 3 (based on Figure 3C-H which can be divisible into at least one window), 4 (the EU338-ATTO 647N probe is directed to the claimed second fluorochrome), 8 (red wine, white wine), and 9 (B. bruxellensis).
Regarding instant claim 2, Branco also discussed an experiment involving a mixed culture of Saccharomyces cerevisiae and D. bruxellensis (e.g., page 4, left column, second paragraph). Branco also discloses a EUK516-ATTO 647 N probe as a positive control for yeasts (page 3, left column, last two paragraphs). It would have been obvious to further include that probe when performing the method rendered obvious by Branco, given the use of S. cerevisiae in wine fermentation (page 1, left column, second paragraph) and because Branco states that it was possible by flow cytometry to detect/identify D. bruxellensis even in the presence of high S. cerevisiae cell densities (abstract). In doing so, then instant claim 2 is rendered obvious, with the second point cloud being part of the biparametric histogram.
Claim 10 is rejected under 35 U.S.C. 103 as being unpatentable over Branco, as evidenced by Van Dorpe as applied to claims 1-4, 8, and 9 above, and further in view of Cognet (US 2016/0274107).
As discussed above, Branco (as evidenced by Van Dorpe) renders obvious claims 1-4, 8, and 9. Branco differs from claim 10 in that Branco does not expressly disclose that the sample is excited at a wavelength greater than or equal to 620 nm, and less than or equal to 750 nm inclusive.
However, Cognet discloses the ATTO-647N can be excited with a 633 nm He-Ne laser (paragraph [0075]).
Before the effective filing date of the claimed invention, when performing the method rendered obvious by Branco, it would have been obvious to the person of ordinary skill in the art to excite the sample at a wavelength of 633 nm (which falls within the claimed range) because that wavelength is appropriate for exciting the fluorescent label, ATTO-647N, used in the method rendered obvious by Branco. Therefore, instant claim 10 is rendered obvious.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN EMILY FERNANDEZ whose telephone number is (571)272-3444. The examiner can normally be reached 10:30am - 7pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Sef
/SUSAN E. FERNANDEZ/ Examiner, Art Unit 1651